{"id":67424,"date":"2026-01-03T18:33:35","date_gmt":"2026-01-03T15:33:35","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/analize\/hla-i-b5701\/"},"modified":"2026-06-19T18:29:58","modified_gmt":"2026-06-19T15:29:58","slug":"hla-i-b5701","status":"publish","type":"product","link":"https:\/\/www.clinica-sante.com\/ro\/analize-farmacogenetica-si-farmacogenomica\/hla-i-b5701\/","title":{"rendered":"HLA I – B*5701"},"content":{"rendered":"

Testul detecteaz\u0103 prezen\u021ba alelei HLA-B*57:01<\/strong>, variant\u0103 genetic\u0103 a genei HLA-B (complexul major de histocompatibilitate clasa I)<\/strong>.<\/p>\n

Aceast\u0103 alel\u0103 este puternic asociat\u0103 cu apari\u021bia unei reac\u021bii de hipersensibilitate imun-mediat\u0103 la administrarea de abacavir<\/strong>, un medicament utilizat \u00een tratamentul infec\u021biei HIV.<\/p>\n

Mecanismul este de tip imunologic, \u00een care moleculele HLA-B*57:01 prezint\u0103 peptide modificate \u00een prezen\u021ba medicamentului, declan\u0219\u00e2nd activarea limfocitelor T citotoxice \u0219i o reac\u021bie sistemic\u0103 sever\u0103.<\/p>\n

Testarea este recomandat\u0103 \u00eenainte de ini\u021bierea tratamentului cu abacavir<\/strong>, deoarece pacien\u021bii pozitivi pentru HLA-B*57:01 prezint\u0103 un risc semnificativ crescut de reac\u021bii adverse severe.<\/p>\n

Indica\u021bii de testare<\/h3>\n
    \n
  • \u00cenainte de ini\u021bierea tratamentului cu abacavir<\/strong><\/li>\n
  • Screening farmacogenetic \u00een infec\u021bia HIV<\/li>\n
  • Istoric de reac\u021bii adverse medicamentoase suspecte<\/li>\n
  • Evaluare de siguran\u021b\u0103 terapeutic\u0103 \u00een antiretrovirale<\/li>\n
  • Medicin\u0103 personalizat\u0103 \u00een infec\u021bii virale cronice<\/li>\n
  • Confirmarea riscului imunologic individual<\/li>\n<\/ul>\n

    Cui se adreseaz\u0103<\/h3>\n
      \n
    • Pacien\u021bilor HIV care urmeaz\u0103 tratament antiretroviral<\/li>\n
    • Medicilor infec\u021bioni\u0219ti<\/li>\n
    • Farmacologilor clinici<\/li>\n
    • Pacien\u021bilor \u00eenainte de prescrierea abacavirului<\/li>\n
    • Centrelor de boli infec\u021bioase \u0219i medicin\u0103 personalizat\u0103<\/li>\n<\/ul>\n

      Metodologie de testare<\/h3>\n
        \n
      • Extrac\u021bie ADN din s\u00e2nge periferic (EDTA)<\/li>\n<\/ul>\n

        Genotipare specific\u0103 HLA-B*57:01 prin metode moleculare (PCR alele-specific \/ PCR-SSP sau PCR \u00een timp real)<\/h3>\n
          \n
        • Detectarea prezen\u021bei sau absen\u021bei alelei HLA-B*57:01<\/li>\n
        • Analiz\u0103 calitativ\u0103 (pozitiv\/negativ)<\/li>\n
        • Interpretare farmacogenetic\u0103 conform ghidurilor clinice interna\u021bionale (CPIC \/ FDA)<\/li>\n<\/ul>\n

          Beneficii \u0219i importan\u021b\u0103 clinic\u0103<\/h3>\n
            \n
          • Contribuie la prevenirea reac\u021biilor de hipersensibilitate severe la abacavir<\/li>\n
          • Reduce riscul de evenimente adverse poten\u021bial letale<\/li>\n
          • Permite selec\u021bia sigur\u0103 a terapiei antiretrovirale<\/li>\n
          • Standard de \u00eengrijire \u00eenainte de tratamentul cu abacavir<\/li>\n
          • Sus\u021bine medicina personalizat\u0103 \u00een infec\u021bia HIV<\/li>\n
          • Contribuie la cre\u0219terea siguran\u021bei tratamentului<\/li>\n
          • Evit\u0103 \u00eentreruperea tratamentului din cauza reac\u021biilor adverse<\/li>\n<\/ul>\n

            Analize asociate recomandate<\/h3>\n

            Farmacogenetic\u0103 HIV \/ antivirale<\/h3>\n
              \n
            • HLA clasa I extins (alte alele cu relevan\u021b\u0103 imunologic\u0103)<\/li>\n
            • Genotipare CYP2B6 (efavirenz metabolism)<\/li>\n
            • Teste farmacogenetice pentru antiretrovirale asociate<\/li>\n<\/ul>\n

              Monitorizare terapeutic\u0103 HIV<\/h3>\n
                \n
              • HIV viral load (ARN HIV)<\/li>\n
              • CD4\/CD8 count<\/li>\n
              • Profil hepatic \u0219i renal<\/li>\n
              • Rezisten\u021b\u0103 genotipic\u0103 HIV (HIV drug resistance testing)<\/li>\n<\/ul>\n

                Imunogenetic\u0103<\/h3>\n
                  \n
                • HLA-B*57:01 confirmator (dac\u0103 exist\u0103 rezultate discordante)<\/li>\n
                • HLA-B*57 \u0219i alte subtipuri HLA-B relevante clinic<\/li>\n<\/ul>\n

                  Prob\u0103 recoltat\u0103 \/ condi\u021bii analiz\u0103<\/h3>\n

                  S\u00e2nge total EDTA<\/h3>\n
                    \n
                  • Nu necesit\u0103 preg\u0103tire special\u0103<\/li>\n<\/ul>\n

                    Documente obligatorii<\/h3>\n
                      \n
                    • Bilet de trimitere \/ recomandare medical\u0103<\/li>\n
                    • Indica\u021bie clinic\u0103 (tratament cu abacavir sau evaluare HIV)<\/li>\n
                    • Date medicale relevante<\/li>\n<\/ul>\n

                      Denumiri alternative<\/h3>\n
                        \n
                      • HLA-B*57:01 genotyping<\/li>\n
                      • Abacavir hypersensitivity test<\/li>\n
                      • HLA B5701 pharmacogenetic test<\/li>\n
                      • HLA-B57 screening<\/li>\n
                      • Abacavir HSR genetic test<\/li>\n
                      • HLA class I pharmacogenetic typing<\/li>\n
                      • HLA-B57:01 allele detection<\/li>\n
                      • Pharmacogenomic HLA-B testing<\/li>\n
                      • HIV pharmacogenetic HLA test<\/li>\n
                      • Biomnis HLA-B5701 assay<\/li>\n<\/ul>\n

                        Particularit\u0103\u021bi ale testului<\/h3>\n

                        Aceast\u0103 analiz\u0103 identific\u0103 prezen\u021ba alelei HLA-B*57:01<\/strong>, un marker genetic validat clinic pentru risc crescut de hipersensibilitate la abacavir. Testul are valoare exclusiv farmacogenetic\u0103 \u0219i nu reprezint\u0103 diagnostic de boal\u0103. Un rezultat negativ reduce semnificativ riscul de reac\u021bie, dar nu exclude complet alte tipuri de reac\u021bii adverse medicamentoase. Interpretarea trebuie realizat\u0103 \u00een context clinic \u0219i terapeutic.<\/p>\n","protected":false},"excerpt":{"rendered":"

                        Analiz\u0103 genetic\u0103 de tip genotipare HLA-B*57:01<\/strong>, utilizat\u0103 pentru identificarea pacien\u021bilor cu risc crescut de reac\u021bie de hipersensibilitate la abacavir<\/strong>. Testul are rol esen\u021bial \u00een farmacogenetic\u0103 \u0219i medicina personalizat\u0103 \u00eenainte de ini\u021bierea tratamentului antiretroviral.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[1209,3226,2876],"product_tag":[],"class_list":["post-67424","product","type-product","status-publish","product_cat-analize","product_cat-farmacogenetica-si-farmacogenomica","product_cat-serviciu-laborator","first","instock","sale","virtual","purchasable","product-type-simple"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t